As Global Sponsor, CooperVision’s Support Expands Language Options and
Extends Access to New Markets
SAN RAMON, CALIF., January 18, 2023—CooperVision, a global leader in myopia management and control, has announced its sponsorship of Ocumetra’s mEYE™ Guide, a parent conversation tool for eye care professionals (ECPs), and mEYE™ Gauge, an axial length estimator. This partnership will broaden access to the tools with additional languages, extending their capabilities to non-English speaking markets worldwide.
Despite rising global prevalence and severity of myopia, ECPs around the world recognize that parents often don't understand the need for myopia management and find that it can take a lot of time to thoroughly explain the concept and treatment options.1
“Just as CooperVision has invested in growing a comprehensive portfolio of evidence-based myopia interventions,2-10 we are dedicated to expanding the accessibility of tools and resources that empower eye care professionals to combat childhood myopia in their practice,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “Our sponsorship of the Ocumetra tools will broaden access to these critical tools to help ensure the disease of myopia is treated with urgency.”
Through intuitive, visual information such as refraction centile charts and a vision simulator packaged into personalized reports, mEYE™ Guide is designed to simplify the conversation between ECPs and parents of children with myopia. With a deeper understanding of myopia, families may be more likely to choose treatment and commit long-term.
An additional Ocumetra tool, mEYE™ Gauge, is also available to ECPs. While ocular biometry remains the gold standard for tracking myopia progression, axial length estimator mEYE™ Gauge empowers ECPs to begin integrating axial length into their myopia management routine without the upfront expense of an optical biometer.
“We are excited about CooperVision's sponsorship which will help bring mEYE™ Guide and mEYE™ Gauge to a broader global audience,” said Prof. Ian Flitcroft, D.Phil, FRCOphth, Ocumetra Co-Founder and Chief Innovation Officer. “At Ocumetra we create tools that help to accelerate the adoption of evidence-based treatments to benefit children with myopia everywhere.”
Through CooperVision’s sponsorship, mEYE™ Guide and mEYE™ Gauge will expand to support additional languages including: Traditional Chinese, Simplified Chinese, Czech, French, German, Hebrew, Hungarian, Italian, Korean, Polish, Portuguese, Russian, and Spanish. Ocumetra has plans underway for other languages as well. With these additional languages, the tools will be able to serve regions with the highest prevalence of myopia around the world.
Ocumetra’s mEYE™ Guide and mEYE™ Gauge are available on a subscription basis. A free trial (and its terms and conditions) is available at cvi.ocumetra.com. At this time, these tools are available in English only. Additional languages to be added in the near future.
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com
Hannah Barry, Counselor, McDougall Communications
firstname.lastname@example.org or +1-585-645-8985
Sulley, et al. Global survey on eye care practitioner perceptions and attitudes regarding myopia and its management. Contact Lens and Anterior Eye. 2021 Feb;44(1):13.
Chamberlain et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci 2019;96:556-567. CVI data on file 2021.
Chamberlain, Arumugam, Jones, et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract):200038
Chamberlain, Arumugam, et al. Myopia progression cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.
Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
Sulley A et al. Experience and subjective responses for children switched from single vision to dual focus myopia control daily disposable contact lenses. BCLA paper presentation 2021.
Jakobsen, Møller. Control of myopia using orthokeratology lenses in Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish Randomized Study: Clinical study Of Near-sightedness; Treatment with Orthokeratology Lenses (CONTROL study). Acta Ophthalmol. 2022 Mar;100(2):175-182.
Lu et al. Efficacy of Trial Fitting and Software Fitting for Orthokeratology Lens: One-Year Follow-Up Study. Eye Contact Lens. 2018 Sep;44(5):339-343.
Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomized controlled, efficacy and safety study (CYPRESS) British Journal of Ophthalmology Published Online First: 01 September 2022.
Laughton et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting.